AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00503477
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Metastatic Tumor
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2009-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00503412
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00503061
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
Phase 1
Completed
- Conditions
- Recurrent GlioblastomaBrain Tumor
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00503204
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Advanced Tumor
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2009-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00502060
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-07-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 104
- Registration Number
- NCT00502567
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
Phase 1
Completed
- Conditions
- Advanced Prostate Adenocarcinoma
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00502164
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML
Phase 1
Completed
- Conditions
- LeukaemiaMyelocyticAcute
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00502385
Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Phase 1
Completed
- Conditions
- Advanced Solid TumorLiver Metastases
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00501605
- Locations
- 🇩🇪
Research Site, Freiburg, Germany
Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 659
- Registration Number
- NCT00501111
- Locations
- 🇬🇧
Research Site, Swindon, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath